JP Morgan Chase’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

JP Morgan Chase’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-36	Closed	–	–	5975
2019 Q4	$0	Buy	+36	New	+$87	﹤0.01%	6053
2019 Q3	–	Sell	-727	Closed	-$4K	–	6099
2019 Q2	$4K	Sell	727 -1,142	-61%	-$4.35K	﹤0.01%	5660
2019 Q1	$6K	Sell	1,869 -53,392	-97%	-$290K	﹤0.01%	5609
2018 Q4	$219K	Sell	55,261 -42,246	-43%	-$540K	﹤0.01%	4559
2018 Q3	$1.93M	Buy	97,507 +82,797	+563%	+$2.09M	﹤0.01%	3492
2018 Q2	$467K	Buy	14,710 +14,054	+2,142%	+$506K	﹤0.01%	4206
2018 Q1	$25K	Buy	656 +201	+44%	+$13.2K	﹤0.01%	5032
2017 Q4	$36K	Buy	+455	New	+$33.7K	﹤0.01%	5002

JP Morgan Chase's MLNT Position: Q1 2020 in Review

JP Morgan Chase sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 36 shares.

JP Morgan Chase first reported a position in MLNT in Q4 2017 and held it in 8 quarters. The position peaked at $1.93M in Q3 2018. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

JP Morgan Chase reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
JP Morgan Chase sold 36 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020.
JP Morgan Chase first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 8 quarters.
JP Morgan Chase's Melinta Therapeutics, Inc. Common Stock position peaked at $1.93M in Q3 2018.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on JP Morgan Chase's 13F filing for Q1 2020, filed 12 May 2020.